The Global Market for Ion Channel Modulators is Projected to Decline to US$7.3 Billion by 2022
Generic Incursion Ushers in New Challenges to Growth
in the Global Ion Channel Modulators Market, According to a New Report by Global Industry Analysts, Inc.
GIA launches comprehensive
analysis of industry trends, growth drivers, market size, and demand forecasts
on the global Ion Channel Modulators market. The global market for Ion Channel Modulators is
projected to decline to US$7.3 billion by 2022, weighed down by patent expirations, generic drug
onslaught and lack of promising drugs in pipeline.
Lack of clear
understanding of the structure and function of ion channels, perpetrated by
their physiological, functional, and structural diversity has stifled research
advances in the area of ion channel modulators. Most first generation ion
channel modulator drugs lack subtype selectivity or specificity, and are
plagued with side effects and restricted therapeutic indices, mandating
research and development of next generation drugs with better safety profile,
higher specificity and superior efficacy. Complexity in the functionality of
ion channels and diversity they entail mandate continued research in
understanding their structure and function, and persevere to develop efficacious
drugs. Despite the valuable genetic information provided by the Human Genome
Project related to ion channels and their use as drug targets, research in this
pace is sluggish resulting in a weak pipeline of products. Issues with target
validation regarding drug action, however, pose hurdles to the development of
more effective drugs. Compounding these issues is the string of patent
expirations in recent years as well as the genericization of the market. With
the leading ion channel modulators losing market exclusivity in recent years
and a few more scheduled to lose patent protection in the foreseeable future,
the market is witnessing revenue erosion and gradually ceding share to generic
formulations.
Ion channels refer to a
class of unique and complex proteins that control the transport of charged
particles (ions) across cell membranes to regulate a wide range of
physiological processes. Cellular functions, such as ion flow, cell volume
regulation and control of membrane potential, hence are dependent on these ion
channels directly involving them in pathophysiology of various maladies. Ion
channel modulators are used in the treatment of a wide array of clinical
conditions, such as hypertension, convulsions, pain, diabetes, and tobacco
dependence. Among these, the calcium channel inhibitors addressing high blood pressure represent one of the
widely used ion channel modulation drugs currently. Sodium channel blockers, potassium channel blockers and potassium channel openers
are some of the other leading drug categories. Voltage-gated sodium channels as well as calcium channels are the targets of most
current pain medications, such as gabapentin, as well as the drugs under
development. Further potential for novel ion channel modulators is immense with
the approach carrying huge potential to alter treatment paradigm of a wide
range of channelopathies, given aging population worldwide, increase in
incidence and prevalence of various targeted diseases particularly
cardiovascular diseases and CNS diseases, and increasing awareness and
healthcare expenditure.
As stated by the new
market research report on Ion Channel Modulators, the U.S. represents the largest market worldwide. Increasing
prevalence of various conditions targeted by ion channel modulators, growing
adoption of these drugs and patent protection for some leading drugs lead to
higher revenues of ion channel modulators in the market. However, Asia-Pacific represents
the fastest growing market worldwide, with a CAGR of 1.8% through the analysis
period. Growing prevalence of targeted conditions in China and India,
increasing awareness, better access to healthcare and an already established
generic base are expected to buoy market growth in the region.
Major players in the market
include Allergan plc, AstraZeneca, Bayer HealthCare Pharmaceuticals, Biogen
Inc., GlaxoSmithKline Plc., H. Lundbeck A/S, Johnson & Johnson, Novartis
AG, Parion Sciences Inc., Pfizer Inc. and Sanofi S.A. among others.
The research report titled
“Ion Channel Modulators: A Global Strategic Business
Report” announced by Global Industry
Analysts Inc., provides a comprehensive
review of market trends, issues, drivers, mergers, acquisitions and other
strategic industry activities of global companies. The report provides market
estimates and projections for Ion Channel Modulators in value terms for all
major geographic markets such as United States, Canada, Japan, Europe (France,
Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific and Rest of
World.
For enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com
Global
Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights
Reserved.
Comments
Post a Comment